Why is Parmax Pharma falling/rising?

Steep Decline in Share Price and Market Underperformance

Parmax Pharma’s recent price movement has been notably negative, with the stock opening the day down by 5.88% and touching an intraday low of ₹30.06, marking an 11.59% drop. The stock has experienced high volatility today, with an intraday range of ₹3.94 and a volatility measure of 6.15%, indicating significant price fluctuations within the trading session. More volume has been traded near the lower price levels, signalling selling pressure. Furthermore, the stock is trading below all major moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, underscoring a bearish technical trend.

In comparison to the broader market, Parmax Pharma has underperformed substantially. Over the past week, the stock has declined by 12.47%, while the Sensex has marginally risen by 0.20%. Year-to-date, the stock has lost nearly 32%, whereas the Sensex has gained over 8%. Over the last one year, Parmax Pharma’s returns have been negative at -34.68%, contrasting with the Sensex’s positive 4.80% gain. This trend extends over longer periods as well, with the stock lagging behind the BSE500 and Sensex indices over three and five years.

Weak Financial Fundamentals Weighing on Investor Confidence

Parmax Pharma’s financial health is a significant factor behind its declining stock price. The company reports a negative book value, indicating that its liabilities exceed its assets, which is a red flag for long-term investors. Over the past five years, the company’s net sales have contracted at an annual rate of 4.56%, while operating profit has grown modestly at 6.65%, reflecting sluggish business growth and limited profitability improvement.

The company’s ability to service its debt is also weak, with an average EBIT to interest coverage ratio of just 0.66, suggesting that earnings before interest and taxes are insufficient to comfortably cover interest expenses. This raises concerns about financial stability and credit risk.

Recent quarterly results have been disappointing. For the nine months ended September 2025, net sales plummeted by 56.46% to ₹9.30 crore. Profit before tax excluding other income reached a low of ₹-2.09 crore, while the net profit after tax was also negative at ₹-2.08 crore. These figures highlight deteriorating operational performance and mounting losses.

Additionally, the company’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) remain negative, further emphasising the risky nature of the stock. Over the past year, profits have declined by 7%, compounding investor concerns amid the stock’s 34.68% negative return during the same period.

Declining Investor Participation and Liquidity Considerations

Investor participation in Parmax Pharma has also diminished, with delivery volumes on 16 December falling by 6.45% compared to the five-day average. This decline in trading interest may exacerbate price weakness as fewer buyers support the stock. Despite this, liquidity remains adequate for trading, although the stock’s wide intraday price swings and gap-down opening reflect heightened risk perceptions among market participants.

Majority shareholding remains with non-institutional investors, which may limit the influence of large institutional buyers who often provide stability and confidence in a stock’s price. The combination of weak fundamentals, poor recent results, and subdued investor interest has culminated in the sharp price decline observed on 17 December.

Conclusion

Parmax Pharma’s share price decline on 17 December is a direct consequence of its deteriorating financial performance, negative earnings, and sustained underperformance relative to market benchmarks. The company’s negative book value, weak debt servicing capacity, and significant contraction in net sales have eroded investor confidence. Coupled with falling investor participation and technical indicators signalling bearish momentum, the stock faces considerable headwinds. Until there is a meaningful turnaround in operational results and financial health, Parmax Pharma’s shares are likely to remain under pressure.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →